Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Sepsis, drotrecogin alfa

Adjunctive immunomodulatory drugs such as drotrecogin-alfa can also be considered for patients with severe sepsis. [Pg.1104]

Xigris Drotrecogin alfa Eli Lilly 11/2001 Severe sepsis NA... [Pg.1426]

Olsen KM, Martin SJ. Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis. Pharmacotherapy 2002 22(12 Pt 2) S196-205. [Pg.701]

Laterre PF, Heiselman D. Management of patients with severe sepsis, treated by drotrecogin alfa (activated). Am J Smg 2002 184(Suppl 6A) S39-46. [Pg.267]

Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003 31 1-11. [Pg.2143]

Drotrecogin is a recombinant human activated protein C that exerts an antithrombotic effect by inhibiting factor Va and factor Villa. It is indicated in the reduction of mortality in adult patients with severe sepsis who have a high risk of death. Drotrecogin alfa Drotrecogin alfa (Xigris) is a recombinant form of human activated protein C that inhibits coagulation by proteolytic inactivation of factor Va and factor Villa. It also has antiinflammatory effects. A 96-hour continuous infusion... [Pg.216]

In a retrospective review of the medical records of 73 patients who had received drotrecogin alfa for sepsis, there were serious bleeding events in 7 of 20 with any baseline susceptibility factor for bleeding and only two of 53 patients without more of the former died and they had higher APACHE II scores and more bloodstream infections [15 ]. [Pg.671]

Taylor BJ, Lee SJ, Waxman K. Bleeding complications with drotrecogin alfa activated (Xigris) a retrospective review of 31 operative and 68 non-operative patients with severe sepsis. Am Surg 2008 74(10) 898-901. [Pg.684]

Woodward B, Cartwright M. Safety of drotrecogin alfa (activated) in severe sepsis data from adult clinical trials and observational studies. J Crit Care 2009 24(4) 595-602. [Pg.684]

Levy M, Levi M, Williams MD, Antonelli M, Wang D, Mignini MA. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med 2009 35(7) 1196-203. [Pg.684]

Drotrecogin Alfa (activated) Severe sepsis Eh Lilly and Company... [Pg.1708]

See other pages where Sepsis, drotrecogin alfa is mentioned: [Pg.1851]    [Pg.1851]    [Pg.1194]    [Pg.1195]    [Pg.345]    [Pg.143]    [Pg.409]    [Pg.268]    [Pg.143]    [Pg.259]    [Pg.276]    [Pg.267]    [Pg.267]    [Pg.185]    [Pg.209]    [Pg.212]    [Pg.217]    [Pg.955]    [Pg.671]    [Pg.684]   
See also in sourсe #XX -- [ Pg.955 ]



SEARCH



Drotrecogin

Drotrecogin alfa

© 2024 chempedia.info